'Garbage scanner' for arteries

40-year-old citizens in the city of Limone sul Garda (Italy) have a habit of smoking with a diet that lacks science, although none of them have found signs of atherosclerosis, regardless of reason. The theory states that subjects like them must first taste the "angry heart" at the age of 30-40.

Unbelievably, all of them have very low levels of 'good' cholesterol (HDL) - GS. Cesare Sirtori (University of Mediolan, Italy) confirmed. More specific studies show that the reason is so strange, because the people of Limone sul Garda are particularly fortunate. The Italian scientist has found in their blood a rare 'good' cholesterol called Apolipoprotein A1 (ApoA1 Milano). It is ApoA1 Milano that plays a role in protecting people from the risk of an effective myocardial infarction rather than HDL which is the property of the majority of humanity.

Immediately after GS's discovery. Cesare Sirtori was announced, American biotechnology company Esperion Therapeutics Inc in England Arbor (Michigan) decided to buy the rights to research to create a brand to prevent atherosclerosis. The results of the recently published drug study show that the brand-name drug ETC-216 not only works to inhibit the development of atherosclerosis, but also 'clears' 'trash'. in arteries after only a few weeks! The more incredible the incredible effect of ETC-216 is, knowing that the most commonly used drugs such as Satyn that lower 'bad' cholesterol levels can eliminate up to 30% risk. myocardial infarction, but does not change the atherosclerosis state.

The "rusty" in the artery

In the United States alone, millions of people die each year from a heart attack and more than ten million others - suffering from anemia. So far, the only effective ' lifesaver ' for the life of anemic heart can only be aortic aneurysm or an artificial artery. So, according to GS. Steven Nissen (Ohio State University), the world's leading cardiologist - If the strengths of ETC-216 are confirmed through studies with more subjects, we can talk about the revolution in treatment of anemia.

Not long ago it was believed that the main factor that increased the risk of myocardial infarction was high blood cholesterol (more than 200mg / dl). But in fact, only ' bad ' cholesterol (LDL-low-density lipoproteins). LDL elements transport cholerterol and its additives from the liver and intestines to the remaining tissues and internal organs, which utilize them to repair cell membranes and synthesize steroids. Once the LDL elements in the blood are too high (higher than 130-160mg / dl), they oxidize and aggregate inside the vascular wall (in some ways similar to the phenomenon of rusty metal pipes). In the heart of the vessel, there will appear atherosclerosis, which increasingly prevents the flow of blood to the heart muscle.

High-density HDL (high-density liporoteins) cholesterol elements are responsible for transferring cholesterol to the liver, where the liver is recycled or excreted from the body to prevent adverse changes that may occur in the coronary arteries. The results of the latest studies show that atherosclerosis is primarily determined by ' good ' cholesterol levels, according to GS studies. Annelies WE Weverling-Rinsburgar (University of Leiden, Netherlands) Blood men with HDL concentrations less than 40 mg / dl are twice as likely to have a heart attack and cerebral ear stroke than those with a high concentration. HDL level is higher than 40 mg / dl.

Atherosclerosis in arterial lumen.

Strength of 'garbage scanner' arteries ETC - 216

According to GS. Nessen, everyone who knows himself has too high LDL levels, needs to try to lower it, but it is generally not enough to avoid the risk of heart attack. Studies using blood cholesterol-lowering drugs were conducted by this scientist for 500 patients during the 18-month period of such determination. Specifically, at a dose of 80 mg / day, the brand name is Lipitor, which will inhibit the progression of atherosclerosis , as opposed to Pravachol - can only slow the disease process. For that reason, according to GS. Henrietta Reicher-Reiss (of Sheba Medical Center, Israel), surely cardiologists will save more people because of myocardial infarction, if they are also allowed to use the drug to increase cholesterol levels. 'kindness '.

The ETC-216 brand includes a high concentration of lipoprotein combination ApoA-1 Milano with Fosfolipid that demonstrates the effect of 'good' cholesterol HDL. For the first time, people were interested in that thanks to experiments by GS. Shaha PK (Cedars-Sinai Medical Ciner in Los Angeles) was conducted in rats and rabbits more than 10 years ago. Synthetic HDL injections have caused atherosclerosis in the animal artery. At that time, people asked for GS. Steven Nissen (Cleveland Clinic Foundation) conducts clinical experiments on the human body. And the work has been implemented in 10 independent research centers in the US.

The 5-week course of treatment (intravenous administration) of a brand-name drug includes ApoA-1 Milano and Fosfolipid compounds, developed with patients with severe atherosclerosis. The researchers carefully examined the level of 'bad fat' in the coronary arteries before and after treatment (applying IVUS ultrasound diagnosis, allowing an accurate picture of the internal state of the vessel wall to be obtained. ). The work was conducted with 57 patients (all with symptoms of pain, high LDL cholesterol levels and coronary artery condition). But no one has to apply arterial angioplasty or coronary artery transplantation. After 5 weeks, in subjects who received the injection, 'bad fat' decreased by an average of 4.2%, while in subjects who received placebo only - the condition of atherosclerosis was severe. GS. Nisen commented on the above work: No medicine has ever yielded such satisfactory results. It really opens up promising prospects .

The results of these studies surprised even the most pessimistic ones. According to GS. Daniel Rader (Philadelphia Medical Research Institute, USA) scientist as an independent expert assessing experimental results, new drugs can become one of the greatest achievements of modern pharmaceutical science . Major pharmaceutical corporations have also started a positive race to research drugs with similar features.